- Home
- EMF vs AMRN Comparison
EMF vs AMRN Comparison
Compare EMF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMF | AMRN |
|---|---|---|
| Founded | 1987 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.7M | 287.9M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | EMF | AMRN |
|---|---|---|
| Price | $22.30 | $13.87 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 24.6K | ★ 75.7K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $16.07 | $12.96 |
| 52 Week High | $24.70 | $20.90 |
Technical Indicators
Market Signals| Indicator | EMF | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 45.99 |
| Support Level | $21.91 | $13.48 |
| Resistance Level | $22.88 | $14.50 |
| Average True Range (ATR) | 0.45 | 0.47 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 19.58 | 38.80 |
Price Performance
Historical ComparisonAbout EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.